Thus, identification of these mutations in thyroid tumors offer a possibility for the use of therapeutic agents that selectively target oncogenic BRAF. Moreover, because of its high sensitivity, it could be also used for the analysis of circulating DNA for patients’ follow-up during treatment. Here, BRAF is linked to thyroid tumor.